Member Info for chromeinvestor

Why the jump today, Hasn't that been out a while?

From PI's to II's

Hi Bamps, I've just taken a look back through your calcs posts. The only thing thing that I cannot ascertain from your posts is what depth you are using and how you arrived at that. I thought the "open at depth" statement simply means that they don't know how far down it goes?

Thanks Paddy, I presumed it was another glitch. Rainy season out there!

Personally I don't think anyone can estimate what resources we have here. The areas included in the IMRE are all open to depth and open at various locations. On top of this, we don't have much data on the areas that were excluded from the IMRE. As GH said, this is just the beginning. Who knows how deep the gold could go? Better grades possibly-could add a large percentage to the inferred resources estimate. It won't happen overnight, but the story and IMHO sp has a long long way to go yet. If your looking to double your money in a a few weeks, then this probably isn't the share for you, but of your looking at a multiple of the current sp over the next 12-24 months, then I don't believe there's a better home for your money.

Seems to be just a white screen for yesterdays image

I particularly like this part:
Beyond COVID-19, we have an ambition to significantly improve early detection of disease
more broadly. The significant expansion of our diagnostics capacity and capabilities since
the start of the pandemic provides a unique opportunity to transform how we address
disease in this country long-term. We see an expanded role for innovative and accessible
diagnostic tools to identify and respond to disease earlier – and will always be looking out
for new methods to reduce and eliminate unnecessary illness.

NHS Test and Trace strategy is backed by an additional £7 billion for its contribution to the
Government’s winter objectives – controlling the rate of reproduction, reducing the spread
of the infection, and saving lives. This includes support for increased testing, including
community testing, new technologies and ongoing improvements to tracing, and takes the
overall funding provided for NHS Test and Trace this financial year to £22 billion.
This is a substantial funding allocation for a necessary part of the response to the
pandemic. The vast majority of this is for testing and reflects the scale of testing that is
happening in the UK.

The next phase
For the next phase we have the following objectives:
Test and Trace Business Plan
19
Further expand the scale of our testing programme
• Continue to expand our testing capacity, including through rapid lateral flow
devices, to increase the proportion of positive cases we find
• Enable our largest employers, critical industries and the cultural and hospitality
sectors to run regular testing programmes
• Support the rollout of community testing in Tier 3 local authorities

Our achievements to date
Since our service was set up, we have:
• Met our testing capacity target of 500,000 tests a day by the end of October, having
processed 41 million tests overall, enabling us to identify over 1.1 million people who
have the virus and helping ensure they and their contacts self-isolate to break chains
of transmission
Test and Trace Business Plan
18
• Increased testing accessibility, by making the digital test booking journey faster and
easier as well as piloting GP and pharmacy testing routes
• Introduced new testing technologies, including LAMP and rapid lateral flow device
tests – supplementing PCR tests with new, rapid turnaround options
• Protected our health and social care settings by testing hospital patients on admission,
care home staff on a weekly basis, and care home residents every 28 days. We have
reduced the turnaround time of results for those tested in social care from over 100
hours in September to an average of 44 hours today – saving lives by breaking chains
of transmission where vulnerability to the virus is highest
• Established over 700 local testing sites (see graphic) to provide more choices and
make testing easier, decreasing the average distance travelled to access a test to 2.4
miles

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/943036/NHS_Test_and_Trace_business_plan.pdf

I couldn't resist it!

Thats what I've now got pencilled in as my best guestimate

Steve, big difference. Only a fraction of whats in the ground has been declared in the MRE. Also GGP have the benefit of telfars infrastructure (processing plant) just up the road, saving billions in set up costs and the normal 6-10 years of development

Will dictate the SP over the medium term. These short term rampers and de-rampers might cause a bit of volatility, but no longer have much impact. A couple of large buys or sells from these funds will set the scene.

Some nice healthy shares slipping from weak holders as far as I'm concerned

L2 52-55 pre open

Market cap £33m as of yesterday-you could'nt make it up

I make that a 56% ownership

For clarity:
Reabold holds its interest in West Newton via its ca. 59 per cent. shareholding in Rathlin, which, in turn, has a 66.67 per cent. interest in PEDL183. In addition, Reabold has a 16.665 per cent. direct licence interest in PEDL 183.